도파민 D4 수용체 길항제인 신규 피페라지닐프로필피라졸유도체, 이의 제조방법 및 이를 포함하는 약학적 조성물
    2.
    发明公开
    도파민 D4 수용체 길항제인 신규 피페라지닐프로필피라졸유도체, 이의 제조방법 및 이를 포함하는 약학적 조성물 有权
    作为多巴胺D4受体拮抗剂的哌嗪衍生物和含有它们的药物组合物

    公开(公告)号:KR1020080082250A

    公开(公告)日:2008-09-11

    申请号:KR1020070022845

    申请日:2007-03-08

    CPC classification number: C07D403/06

    Abstract: A piperazinyl-propyl-pyrazole derivative is provided to show excellent dopamine D4 affinity, inhibit the psychotic action of a mouse induced by apomorphine and exhibit relatively weak side effect at a mouse rotarod test, thereby being effectively used as a therapeutic and prophylactic agent of central nervous system diseases. A piperazinyl-propyl-pyrazole derivative is represented by a formula(1). In the formula(1), R^1 is C1-10 alkyl, or substituted or unsubstituted aryl or heteroaryl; one of R^2 or R^3 is H, and the other one of R^2 or and R^3 is C1-10 alkyl, benzyl, or substituted or unsubstituted aryl or heteroaryl; each R^4, R^5, R^6, and R^7 is independently H or C1-10 alkyl; each R^8, R^9, R^10, R^11 and R^12 is independently H, halogen, C1-10 alkyl, C1-C10 alkoxy, bis(substituted or unsubstituted aryl)alkylene, benzyl, nitro, hydroxy, cyano, amino, mono- or di-alkylamino, alkylcarbonylamino, aminosulfonyl, mono- or di-alkylaminosulfonyl, alkylcarbonyl, or alkyloxycarbonyl; and a dotted line is a single-bonded line or a double bond, wherein the aromaticity of a pyrazole-ring should be maintained, the aryl is phenyl, the heteroaryl is thiophenyl or pyridyl, and the substituted aryl or heteroaryl is an aryl or a heteroaryl substituted with one to three substituent(s) selected from the group consisting of halogen, nitro, C1-10 alkyl, C1-10 alkoxy, C1-10 haloalkyl, and C1-10 haloalkoxy. A method for preparing the piperazinyl-propyl-pyrazole derivative comprises a step of subjecting a pyrazole aldehyde derivative represented by a formula(2) and a piperazine derivative represented by a formula(3) to a reductive amination reaction. A pharmaceutical composition for treating central nervous system diseases comprise the compound of the formula(1).

    Abstract translation: 提供哌嗪基 - 丙基 - 吡唑衍生物以显示出优异的多巴胺D4亲和力,抑制阿扑吗啡诱导的小鼠的精神病作用,并且在小鼠旋转试验中显示相对较弱的副作用,从而有效地用作中枢的治疗和预防剂 神经系统疾病 哌嗪基 - 丙基 - 吡唑衍生物由式(1)表示。 在式(1)中,R 1是C 1-10烷基或取代或未取代的芳基或杂芳基; R 2或R 9中​​的一个为H,R 2和R 3中的另一个为C 1-10烷基,苄基或取代或未取代的芳基或杂芳基; 每个R 4,R 5,R 6和R 9独立地是H或C 1-10烷基; 每个R 8,R 9,R 10,R 11和R 12独立地是H,卤素,C 1-10烷基,C 1 -C 10烷氧基,双(取代或未取代的芳基)亚烷基,苄基,硝基,羟基 氰基,氨基,一或二烷基氨基,烷基羰基氨基,氨基磺酰基,一或二烷基氨基磺酰基,烷基羰基或烷氧基羰基; 并且虚线是单键或双键,其中应保持吡唑环的芳香性,芳基为苯基,杂芳基为噻吩基或吡啶基,取代的芳基或杂芳基为芳基或 被一至三个选自卤素,硝基,C 1-10烷基,C 1-10烷氧基,C 1-10卤代烷基和C 1-10卤代烷氧基的取代基取代的杂芳基。 制备哌嗪基 - 丙基 - 吡唑衍生物的方法包括将由式(2)表示的吡唑醛衍生物和由式(3)表示的哌嗪衍生物进行还原胺化反应的步骤。 用于治疗中枢神经系统疾病的药物组合物包含式(1)的化合物。

Patent Agency Ranking